Skip to main content

Table 2 Hazard ratios of breast cancer disease-free survival for several basic characteristics by breast cancer subtyping

From: Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival

   

Molecular subtyping

 

All

      

Five subtypes

Four subtypes

Variables

(N = 951)

IHC-Luminal A

(N = 486)

IHC-Luminal B

(N = 123)

IHC-HER2

(N = 113)

IHC-BLBC

(N = 139)

IHC-QNBC/5NP

(N = 90)

IHC-TNBC

(N = 229)

 

HR(N of event)

HR(N of event)

HR(N of event)

HR(N of event)

HR(N of event)

HR(N of event)

HR(N of event)

 

(95%CI)

p-value

(95%CI)

p-value

(95%CI)

p-value

(95%CI)

p-value

(95%CI)

p-value

(95%CI)

p-value

(95%CI)

p-value

Age Group (yr)

              

   > 50

1.00(174/590)

 

1.00(79/297)

 

1.00(32/87)

 

1.00(25/51)

 

1.00(22/97)

 

1.00(16/58)

 

1.00(38/155)

 

   ≥ 50

0.73(82/361)

 

0.72(38/189)

 

0.88(12/36)

 

0.42(16/62)

 

0.70(7/42)

 

1.07(10/32)

 

0.89(17/74)

 
 

(0.55-0.96)

0.020

(0.49-1.07)

0.856

(0.45-1.71)

1.0

(0.21-0.79)

0.056

(0.29-1.60)

1.0

(0.48-2.37)

1.0

(0.50-1.58)

1.0

Tumor size (cm)

              

   ≤ 2 cm

1.00(77/392)

1.00(38/228)

 

1.00(16/39)

 

1.00(8/35)

 

1.00(9/52)

 

1.00(6/38)

 

1.00(15/90)

 

   2-5 cm

1.62(146/493)

1.86(23/75)

 

0.73(23/75)

 

1.93(25/64)

 

1.04(14/76)

 

2.72(17/47)

 

1.59(31/123)

 
 

(1.23-2.14)

0.001

(1.25-2.77)

0.016

(0.38-1.38)

1.0

(0.87-4.27)

0.864

(0.45-2.39)

1.0

(1.07-6.89)

0.288

(0.86-2.94)

1.0

   > 5cm

3.14(33/66)

 

3.32(12/27)

 

1.34(5/9)

 

2.65(7/14)

 

4.04(6/11)

 

4.67(3/5)

 

4.30(8/16)

 
 

(2.08-4.72)

< 0.001

(.1.73-6.35)

< 0.001

(0.49-3.67)

1.0

(0.96-7.30)

0.480

(1.43-11.22)

0.064

(1.16-18.22)

0.240

(1.90-9.82)

0.008

LN involvement

              

   Negative

1.00(85/503)

1.00(31/248)

 

1.00(15/53)

 

1.00(18/64)

 

1.00(12/89)

 

1.00(9/49)

 

1.00(21/138)

 

   Positive

2.54(171/448)

3.28(86/238)

 

1.60(29/70)

 

1.88(22/49)

 

2.75(17/50)

 

2.83(17/41)

 

2.83(34/91)

 
 

(1.96-3.30)

< 0.001

(2.17-4.95)

0.001

(0.86-2.98)

0.980

(1.01-3.51)

0.376

(1.32-5.77)

0.045

(1.26-6.36)

0.096

(1.64-4.89)

< 0.001

AJCC stage

              

   I

1.00(36/254)

1.00(14/148)

 

1.00(8/19)

 

1.00(4/22)

 

1.00(5/38)

 

1.00(5/27)

 

1.00(10/65)

 

   II

1.62(106/467)

2.62(50/221)

 

0.55(18/69)

 

2.02(19/57)

 

1.24(13/78)

 

0.79(6/42)

 

1.03(19/120)

 
 

(1.02-2.14)

0.001

(1.45-4.74)

0.008

(0.24-1.26)

1.0

(0.68-5.94)

1.0

(0.44-3.48)

1.0

(0.24-3.48)

1.0

(0.48-2.20)

1.0

   III

3.14(114/230)

 

5.86(53/117)

 

1.32(18/35)

 

3.59(17/34)

 

4.31(11/23)

 

6.30(15/21)

 

5.14(26/44)

 
 

(2.08-4.72)

< 0.001

(3.24-10.55)

0.001

(0.58-3.04)

1.0

(1.21-10.67)

0.176

(1.49-12.41)

0.056

(2.27-17.5)

0.001

(2.47-10.66)

< 0.001

Adjuvant chemotherapy

              

   Not done

1.00(43/155)

1.00(17/95)

 

1.00(9/20)

 

1.00(10/22)

 

1.00(6/10)

 

1.00(1/8)

 

1.00(7/18)

 

   Done

0.98(213/796)

1.57(100/391)

 

0.63(35/103)

 

0.69(30/91)

 

0.24(23/129)

 

3.13(25/82)

 

0.59(48/211)

 
 

(0.71-1.36)

0.915

(0.94-2.64)

0.083

(0.31-1.32)

0.226

(0.34-1.42)

0.312

(0.10-0.60)

0.002

(0.43-23.2)

0.26

(0.26-1.30)

1.0

  1. IHC: immunohistochemistry, LN: lymph node
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us